Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients-Reference-Cited by-同舟云学术

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

Published:2009-08 Issue:8 Volume:11 Page:786-794
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:

Author:

Heise T.,Graefe-Mody E. U.,Hüttner S.,Ring A.,Trommeshauser D.,Dugi K. A.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2009.01046.x/fullpdf

Reference36 articles.

1. Gut peptides and type 2 diabetes mellitus treatment;Ahrén;Curr Diab Rep,2003

2. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes;Drucker;Expert Opin Investig Drugs,2003

3. Therapeutic strategies based on glucagon-like peptide 1;Deacon;Diabetes,2004

4. What do we know about the secretion and degradation of incretin hormones?;Deacon;Regul Pept,2005

5. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug;Idris;Diabetes Obes Metab,2007

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin;Drug Delivery and Translational Research;2024-05-13

2. Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study;Diabetes Therapy;2024-03-18

3. A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin;Journal of Pharmaceutical Sciences;2024-01

4. Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles;Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: From Basic Concepts to Applications;2024

5. Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days;Experimental and Clinical Endocrinology & Diabetes;2022-11-07